Teva opposes Corcept's summary judgment motion in US antitrust litigation
( November 7, 2026, 01:09 GMT | Official Statement) -- MLex Summary: Teva Pharmaceuticals urged a California federal judge to deny Corcept Therapeutics' motion for summary judgment in their antitrust dispute. Teva alleges that Corcept imposed a "one-of-a-kind exclusive-dealing agreement" on the only pharmacies authorized to distribute Korlym, Corcept's brand-name treatment for Cushing's syndrome. In its filing, Teva argued that there are multiple grounds on which a reasonable jury could conclude that Corcept's exclusive-dealing agreements foreclosed competition in a substantial share of the relevant market.See attached filing....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.